Introduction of managed entry agreements in Korea: Problem, policy, and politics

Keyphrases

• Politics 100%
• Managed Entry Agreements 100%
• Rare Diseases 20%
• Australia 10%
• Clinical Data 10%
• South Korea 10%
• United Kingdom 10%
• Extensive Literature Review 10%
• Major Diseases 10%
• Italy 10%
• Patient Access 10%
• Rare Cancer 10%
• Orphan Drugs 10%
• Agreement Implementation 10%
• Kappa Coefficient 10%
• Reimbursement Mechanisms 10%
• Insurance Coverage 10%
• Three-stream 10%
• Cancer Disease 10%
• Anticancer Agents 10%
• Window Model 10%
• Outcome-based Contracts 10%
• Benefit System 10%
• Policy Streams 10%
• Practical Effects 10%
• Kingdon 10%
• Practical Management 10%
• Pricing Scheme 10%
• Policy Windows 10%
• Problem Stream 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Rare Disease 100%
• Disease 50%
• Anticarcinogen 50%
• Orphan Drug 50%

Medicine and Dentistry

• Medicine 100%
• Malignant Neoplasm 33%
• Rare Disease 33%
• Disease 16%
• Anticarcinogen 16%
• Kappa Statistics 16%
• Orphan Drug 16%